Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024
Translational Breast Cancer Research · 2024-07 · 5 · 18-18
DOI: 10.21037/tbcr-24-31 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Translational Breast Cancer Research, 2024-07. Verfasst von Jianbin Li und 16 weiteren Autor:innen. Beteiligte Einrichtung: Senior Department of Oncology, Fifth Medical Center of PLA General Hospital, Beijing, China. Die Arbeit wurde bisher 88-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Developing guidelines for the diagnosis and treatment of common cancers in China based on the evidence-based practice, the availability of diagnosis and treatment products, and the up-to-date advances in precision medicine is one of the basic tasks of the Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Committee.
Methods
Protocols with high evidence level and good availability are used as the Level I recommendations; protocols with relatively high evidence level but slightly lower expert consensus or with poor availability are used as the Level II recommendations; and protocols that are clinically applicable but with low evidence level are regarded as the Level III recommendations. Based on the findings of clinical research at home and abroad and the opinions of CSCO BC experts, the CSCO BC guidelines determine the levels of recommendations for clinical application.
Results
For human epidermal growth factor receptor 2 (HER2)-positive breast cancer, a combination of trastuzumab and pertuzumab regimen were recommended as Level I recommendation for neoadjuvant and first line metastatic breast cancer. Pyrotinib is also recommended as Level I recommendation in first line and second line therapy according to the latest studies conducted in China. Antibody drug conjugates was also recommended for patients with trastuzumab progression. For triple negative breast cancer, immunotherapy in early and metastatic breast cancer was highlighted and listed as new chapters in this version of guideline. For hormone receptor (HR)-positive breast cancer, cyclin dependent kinase 4/6 (CDK4/6) was recommended in different stages, especially in adjuvant therapy. There was also a new chapter for HER2-low breast cancer stratified by HR status.
Conclusions
We firmly believe that evidence-based, availability-concerned, and consensus-based guidelines will be more feasible for clinical practice in China and in other countries with similar situations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Senior Department of Oncology, Fifth Medical Center of PLA General Hospital, Beijing, China.
- Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
- Department of Breast Cancer, Guangdong Provincial People's Hospital, Southern Medical University, Guangzhou, China.
- Breast Cancer Center, Cancer Hospital of Fudan University, Shanghai, China.
- Department of Radiotherapy, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Pathology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Zitieren
APA
Li, J., Hao, C., Wang, K., Zhang, J., Chen, J., Liu, Y., Nie, J., Yan, M., Liu, Q., Geng, C., Wang, X., Wang, H., Wang, S., Wu, J., Yin, Y., Song, E., & Jiang, Z. (2024). Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024. Translational Breast Cancer Research, 5, 18-18. https://doi.org/10.21037/tbcr-24-31
Vancouver
Li J, Hao C, Wang K, Zhang J, Chen J, Liu Y, et al. Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024. Translational Breast Cancer Research. 2024;5:18-18. doi:10.21037/tbcr-24-31
BibTeX
@article{Li2024,
author = {Li, Jianbin and Hao, Chunfang and Wang, Kun and Zhang, Jian and Chen, Jiayi and Liu, Yueping and Nie, Jianyun and Yan, Min and Liu, Qiang and Geng, Cuizhi and Wang, Xiaojia and Wang, Haibo and Wang, Shusen and Wu, Jiong and Yin, Yongmei and Song, Erwei and Jiang, Zefei},
title = {Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024},
journal = {Translational Breast Cancer Research},
year = {2024},
volume = {5},
pages = {18--18},
doi = {10.21037/tbcr-24-31}
}
EUVIMED